Heterogeneity in reducing recurrent ischemic stroke among subgroups
atrial fibrillation, diabetes, AIS, ischemic stroke
RECURRENT CEREBRAL INFARCTION, HYPERLIPIDEMIA, ISCHEMIC STROKE, ATRIAL FIBRILLATION, HYPERTENSION, DIABETES
To explore the heterogeneity of the two different therapy regimens in reducing the risk of recurrent ischemic stroke for AIS patients within 90 days, we performed a subgroup analysis according to the aforementioned stratification. The intensive rosuvastatin therapy plus 7-day DAPT always effectively reduced the risk of recurrent ischemic stroke, with the HR value of each subgroup located on the left side of the invalid line, except the subgroup with bNIHSS ≤ 2. It was particularly efficient in these subgroups with high-risk factors such as the elderly, hypertension, diabetes, hyperlipidemia, or prior-stroke, non-antiplatelet treatment, and high-bNIHSS (3–10 points), while it was less efficient in female, OMT > 48 h, and prior atrial fibrillation subgroups (Fig. Hazard ratio for the recurrent cerebral infarction in subgroups at 90 days